Abstract Details

Title Medical �鶹��ýӳ�� Improves Knowledge Among Neurologists of Newly Approved Pharmacotherapies for the Management of Wearing-Off in Parkinson Disease

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 077

Objective

An online activity was developed to assess the ability of an online medical education program to improve awareness among neurologists’ of recently approved adjunctive medications for the reduction of wearing-off symptoms.

Background Prolonged use of levodopa/carbidopa in patients with Parkinson disease (PD) is associated with the development of wearing-off symptoms. There several adjunctive therapies designed to reduce wearing-off symptoms. However, none of the options are equally effective or well tolerated for all patients, necessitating the need for education on how best to use available therapies.

Design/Methods The CME activity was an online 30-minute video-based slide presentation with a single faculty expert in the management of PD. �鶹��ýӳ��al effect was assessed by comparing a matched sample of neurologists’ responses to four identical questions pre- and post-activity. A chi-square test identified significant differences between pre- and post-assessment responses. Cramer’s V was used to calculate the effect size of the online education. Data were collected between March 11, 2020 and May 13, 2020.

Results

Activity participation resulted in a noticeable educational effect among neurologists (n=265; V=.115, P<.001). The following areas showed significant (P <.05) pre- vs post-educational improvements: the mechanism of action of istradefylline and the dosing of opicapone associated with the best efficacy in phase 3 trials. The program was not effective in improving awareness of the striatum as the brain region involved in the development of wearing-off symptoms (86% of neurologists’ knew this prior to education). 43% of neurologists’ had a measurable improvement in confidence in developing a personalized plan for the management of wearing-off symptoms in patients with PD.

Conclusions The results indicated that this CME-certified 30-minute online program was effective at improving knowledge among neurologists’ of therapies to treat wearing-off symptoms in PD. Future education should address the evidence-based use of therapies for the management of wearing-off symptoms in PD.

Authors/Disclosures
Jovana Lubarda PRESENTER	Jovana Lubarda has nothing to disclose.
Thomas Finnegan, Jr., PhD (Medscape �鶹��ýӳ��)	Dr. Finnegan has nothing to disclose.
Lisette Arnaud-Hevi (Medscape)	No disclosure on file
	No disclosure on file
Daniel O. Claassen, MD, F�鶹��ýӳ�� (Vanderbilt University Medical Center)	Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics . Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI.